



DT06 Rec'd PCT/PTO 30 SEP 2002

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
100 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

RECEIVED

MAR 05 2003

TECH CENTER 1600/2900

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

September 24, 2002

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

September 24, 2002

Date

Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 10/088,549 entitled "ASSAY TO DETECT SUBSTANCES USEFUL FOR THERAPY" by Erik Nielsen et al.*
Our Reference: DEBE:007US
Client Reference: GI-003 PCT/US AD/sch


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1, B1-B8, C1-26).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/DEBE:007US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl.: as noted

25210144.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Erik Nielsen *et al.*

Serial No.: 10/088,549

Filed: March 15, 2002

For: ASSAY TO DETECT SUBSTANCES
USEFUL FOR THERAPY

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: DEBE:007US

RECEIVED
MAR 05 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

September 24, 2002

Date

Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/DEBE:007US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: September 24, 2002

Form PTO-1449 (modified)

Atty. Docket No.

DEBE:007US

Serial No.

10/088,549

List of Patents and Publications for Applicant's

Applicant

Erik Nielsen *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

March 15, 2002

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,698,428	12/16/97	Abo <i>et al.</i>	435	194	1/10/97

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 0856583	8/5/98	Europe			
	B2	WO 97/00955	1/9/97	PCT			
	B3	WO 98/18942	5/7/98	PCT			
	B4	WO 98/20127	5/14/98	PCT			
	B5	WO 98/37196	8/27/98	PCT			
	B6	WO 98/42839	10/1/98	PCT			
	B7	WO 99/13079	3/18/99	PCT			
	B8	WO 99/52941	10/21/99	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Amano <i>et al.</i> , "Identification of a putative target for Rho as the serine-threonine kinase protein kinase N," <i>Science</i> , 271:648-650, 1996.
	C2	Benard <i>et al.</i> , "Potential drug targets: small GTPases that regulate leukocyte function," <i>Trends in Pharmacological Sciences</i> , 20(9):365-370, 1999.
	C3	Bradke and Dotti, "Neuronal polarity: vectorial cytoplasmic flow precedes axon formation," <i>Neuron</i> , 19:1175-1186, 1997.
	C4	Bradke and Dotti, "Videomicroscopy of microinjected hippocampal neurons," In: <i>Microinjection and Transgenesis: Strategies and Protocols</i> , Arreguli and Carrancá (eds.), Springer, Germany: Springer Verlag, Chapter 4:81-94, 1997.

25179797.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

Atty. Docket No.
DEBE:007USSerial No.
10/088,549

List of Patents and Publications for Applicant's

Applicant
Erik Nielsen *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
March 15, 2002Group:
UnknownU.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
*See Page 1*RECEIVED
MAR 05 2003
TECH-CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C5	Caraglia <i>et al.</i> , "Up-regulated EGF receptors undergo to rapid internalization and ubiquitin-dependent degradation in human cancer cells exposed to 8-C1-cAMP," <i>FEBS Letters</i> , 447:203-208, 1999.
	C6	Chistoforidis <i>et al.</i> , "Phosphatidylinositol-3-OH kinases are Rab5 effectors," <i>Nat. Cell Biol.</i> , 1:249-252, 1999.
	C7	Chistoforidis <i>et al.</i> , "The Rab5 effector EEA1 is a core component of endosome docking," <i>Nature</i> , 397:621-625, 1999.
	C8	Christoforidis and Zerial, "Purification and identification of novel Rab effectors using affinity chromatography," <i>Methods</i> , 20:403-410, 2000.
	C9	De Renzis <i>et al.</i> , "Divalent Rab effectors regulate the sub-compartmental organization and sorting of early endosomes," <i>Nature Cell Biology</i> , 4:124-133, 2002.
	C10	Field <i>et al.</i> , "Cloning and characterization of CAP, the <i>S. cerevisiae</i> gene encoding the 70 kd adenylyl cyclase-associated protein," <i>Cell</i> , 61:319-327, 1990.
	C11	Geller <i>et al.</i> , "Long-term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylyl cyclase from a herpes simplex virus type 1 vector," <i>Proc. Natl. Acad. Sci. USA</i> , 90:7603-7607, 1993.
	C12	Gournier <i>et al.</i> , "Two distinct effectors of the small GTPase Rab5 cooperate in endocytic membrane fusion," <i>Embo J.</i> , 17:1930-1940, 1998.
	C13	Horiuchi <i>et al.</i> , "A novel Rab5 GDP/GTP exchange factor complexed to Rabaptin-5 links nucleotide exchange to effector recruitment and function," <i>Cell</i> , 90:1149-1159, 1997.
	C14	Matoskova <i>et al.</i> , "RN-tre identifies a family of tre-related proteins displaying a novel potential protein binding domain," <i>Oncogene</i> , 12:2563-2571, 1996.
	C15	McBride <i>et al.</i> , "Oligomeric complexes link Rab5 effectors with NSF and drive membrane fusion via interactions between EEA1 and syntaxin 13," <i>Cell</i> , 98:377-386, 1999.
	C16	McMahon, "VEGF receptor signaling in tumor angiogenesis," <i>Oncologist</i> , 5 (Suppl 1):3-10, 2000.
	C17	Murphy <i>et al.</i> , "Endosome dynamics regulated by a novel Rho protein," <i>Nature</i> , 384:427-432, 1996.

25179797.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

DEBE:007US

10/088,549

List of Patents and Publications for Applicant's

Applicant

Erik Nielsen *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

March 15, 2002

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C18	Nielsen <i>et al.</i> , "Rab5 regulates motility of early endosomes on microtubules," <i>Nat Cell Biol.</i> , 1:376-382, 1999.
	C19	Nielsen <i>et al.</i> , "Rabenosyn-5, a novel Rab5 effector, is complexed with hVPS45 and recruited to endosomes through a FYVE finger domain," <i>J. Cell Biology</i> , 151:601-612, 2000.
	C20	Siddhanta <i>et al.</i> , "Distinct roles for the p110alpha and hVPS34 phosphatidylinositol 3'-kinases in vesicular trafficking, regulation of the actin cytoskeleton, and mitogenesis," <i>J. Cell Biol.</i> , 143:1647-1659, 1998.
	C21	Simonsen <i>et al.</i> , "EEA1 links phosphatidylinositol 3-kinase function to Rab5 regulation of endosome fusion," <i>Nature</i> , 394:494-498, 1998.
	C22	Sonnichsen <i>et al.</i> , "Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11," <i>J. Cell Biology</i> , 149:901-913, 2000.
	C23	Sorkin <i>et al.</i> , "Recycling of epidermal growth factor-receptor complexes in A431 cells identification of dual pathways," <i>J. Cell Biol.</i> , 112:55-63, 1991.
	C24	Stenmark <i>et al.</i> , "Rabaptin-5 is a direct effector of the small GTPase Rab5 in endocytic membrane fusion," <i>Cell</i> , 83:423-432, 1995.
	C25	Uehata <i>et al.</i> , "Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension," <i>Nature</i> , 389:990-994, 1997.
	C26	Zerial and McBride, "Rab proteins as membrane organizers," <i>Molecular Cell Biology</i> , 2:107-117, 2001.

25179797.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT